Treatment Outcomes Stratified by Baseline Immunological Status Among Young Children Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Resource-Limited Settings.

Hdl Handle:
http://hdl.handle.net/10144/18270
Title:
Treatment Outcomes Stratified by Baseline Immunological Status Among Young Children Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Resource-Limited Settings.
Authors:
O'Brien, D P; Sauvageot, D; Olson, D; Schaeffer, M; Humblet, P; Pudjades, M; Ellman, T; Zachariah, R; Szumilin, E; Arnould, L; Reid, T
Journal:
Clinical Infectious Diseases
Abstract:
A study of 568 children aged <5 years who commenced nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings revealed good early outcomes. After 12 months of antiretroviral therapy, survival probability was 0.89 (95% confidence interval, 0.86-0.92), with no significant difference among children stratified on the basis of baseline immunological levels; 62% attained a CD4 cell percentage >25%, and 7% continued to have a CD4 cell percentage <15%.
Affiliation:
AIDS Working Group, Médecins Sans Frontières, Paris, France. daniel.obrien@amsterdam.msf.org
Publisher:
Published by: Infectious Diseases Society of America
Issue Date:
1-May-2007
URI:
http://hdl.handle.net/10144/18270
DOI:
10.1086/513433
PubMed ID:
17407046
Additional Links:
http://www.journals.uchicago.edu/page/cid/brief.html
Language:
en
ISSN:
1537-6591
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Brien, D P-
dc.contributor.authorSauvageot, D-
dc.contributor.authorOlson, D-
dc.contributor.authorSchaeffer, M-
dc.contributor.authorHumblet, P-
dc.contributor.authorPudjades, M-
dc.contributor.authorEllman, T-
dc.contributor.authorZachariah, R-
dc.contributor.authorSzumilin, E-
dc.contributor.authorArnould, L-
dc.contributor.authorReid, T-
dc.date.accessioned2008-02-14T11:46:31Z-
dc.date.available2008-02-14T11:46:31Z-
dc.date.issued2007-05-01-
dc.identifier.citationTreatment Outcomes Stratified by Baseline Immunological Status Among Young Children Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Resource-Limited Settings. 2007, 44 (9):1245-8 Clin. Infect. Dis.-
dc.identifier.issn1537-6591-
dc.identifier.pmid17407046-
dc.identifier.doi10.1086/513433-
dc.identifier.urihttp://hdl.handle.net/10144/18270-
dc.description.abstractA study of 568 children aged <5 years who commenced nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings revealed good early outcomes. After 12 months of antiretroviral therapy, survival probability was 0.89 (95% confidence interval, 0.86-0.92), with no significant difference among children stratified on the basis of baseline immunological levels; 62% attained a CD4 cell percentage >25%, and 7% continued to have a CD4 cell percentage <15%.-
dc.language.isoen-
dc.publisherPublished by: Infectious Diseases Society of America-
dc.relation.urlhttp://www.journals.uchicago.edu/page/cid/brief.html-
dc.rightsArchived on this site with permission and copyright by the Infectious Diseases Society of Americaen_GB
dc.subject.meshAcquired Immunodeficiency Syndrome-
dc.subject.meshCD4 Lymphocyte Count-
dc.subject.meshChild, Preschool-
dc.subject.meshDeveloping Countries-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshFemale-
dc.subject.meshHealth Resources-
dc.subject.meshHumans-
dc.subject.meshImmune Tolerance-
dc.subject.meshMale-
dc.subject.meshProbability-
dc.subject.meshReverse Transcriptase Inhibitors-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.titleTreatment Outcomes Stratified by Baseline Immunological Status Among Young Children Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Resource-Limited Settings.-
dc.contributor.departmentAIDS Working Group, Médecins Sans Frontières, Paris, France. daniel.obrien@amsterdam.msf.org-
dc.identifier.journalClinical Infectious Diseases-

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.